Web annex 2: Carbetocin versus placebo or no treatment
Evidence to decision framework
The WHO Academy’s mobile learning app was developed specifically for health workers and is designed to enable them to expand their life-saving skills to battle COVID-19. It delivers mobile access... to a wealth of COVID-19 knowledge resources developed by WHO, including up-to-the-minute guidance, tools, training, and virtual workshops to support health workers in caring for patients infected by COVID-19 and in protecting themselves as they do their critical work.
With content in seven languages – Arabic, Chinese, English, French, Portuguese, Russian and Spanish – the app focuses on providing health workers with critical, evidence-based information and tools to respond to the pandemic.
more
HIV-1 drug resistance (HIVDR) genotyping is an essential component of the WHO global HIVDR surveillance strategy. Plasma “gold standard” specimen type for HIVDR genotyping, but its use may not be feasible in rural, remote areas in low- and middl...e-income countries, since preparing and storing it require personnel and laboratory infrastructure that are often lacking. An alternative specimen type is dried blood spots (DBS), which can be made without special laboratory processing. DBS are more easily transported than plasma because they can be shipped at ambient temperature as non-hazardous materials using regular mail or courier services.
3rd edition
more
WHO‘s Global Strategy to Accelerate the Elimination of Cervical Cancer, launched today, outlines three key steps: vaccination, screening and treatment. Successful implementation of all three could reduce more than 40% of new cases of the disease a...nd 5 million related deaths by 2050.
more
WHO’s Global Health Estimates (GHE) provide the latest available data on death and disability globally, by region and country, and by age, sex and cause. The latest updates include global, regiona...l and country trends from 2000 to 2019 inclusive. By providing key insights on mortality and morbidity trends, these estimates are a powerful tool to support informed decision-making on health policy and resource allocation.
The next update to these estimates will include an assessment of the direct and indirect impact of the COVID-19 pandemic on mortality and morbidity.
more
The WHO SAGE values framework for the allocation and prioritization of COVID-19 vaccination is intended to offer guidance on the prioritization of groups for vaccination when vaccine supply is limited. It provides a values foundation for the object...ives of COVID-19 vaccination programmes and links those to target groups for vaccination. This information is valuable to countries and globally while specific policies will be developed once vaccines become available.
This document it available in Arabic, Chinese English, French, Portuguese and Russian
more
The WHO SAGE values framework for the allocation and prioritization of COVID-19 vaccination is intended to offer guidance on the prioritization of groups for vaccination when vaccine supply is limited. It provides a values foundation for the object...ives of COVID-19 vaccination programmes and links those to target groups for vaccination. This information is valuable to countries and globally while specific policies will be developed once vaccines become available.
This document it available in Arabic, Chinese and Russian
more
The WHO Labour Care Guide is a tool that aims to support good-quality, evidence-based, respectful care during labour and childbirth, irrespective of the setting or level of health care. This manual ...has been developed to help skilled health personnel to successfully use the WHO Labour Care Guide. The manual will also be of interest to staff involved in training health care personnel, health-care facility managers, and implementers and managers of maternal and child health services.
more
When can we expect a vaccine for COVID-19? How will we ensure that it is safe? Who should be vaccinated first and why? Find out the answers to these and other questions.
How do vaccines work to protect us? What are the vaccine technologies in the pipeline and how do we ensure safe vaccines? Dr Katherine O’ Brien explains in Science in 5 !
How concerned should we be about the new variants of SARS CoV 2 which cause COVID-19? Is it unusual for viruses to change and mutate? Do vaccines protect against these variants and what can you do to protect yourself? WHO’s Chief Scientist Dr Soum...ya Swaminathan explains in Science in 5
more
Why are experts concerned about COVID-19 and antibiotics? And what can you do about it? Learn about antibiotics and COVID-19 from WHO’s Dr Hanan Balkhy in Science in 5
This document outlines the evaluation process that WHO undertakes to assess novel tools and strategies targeted at VBDs. Its aim is to articulate the linkage between the generation of evidence that demonstrates public ...ight medbox">health impact of novel interventions, and the development of policy recommendations based on the generated data. The document defines standards for the evaluation process, as well as the steps that an applicant needs to undertake, along with some guiding principles that aim to support applicants in the development of submissions with WHO.
more
The PQS on-line catalogue includes details of all immunization-related products currently pre-qualified by WHO for procurement by United Nations agencies. The catalogue is produced and maintained by the Quality, Safety and Standards group in the Imm...unization, Vaccine and Biologicals Department of WHO, Geneva. It replaces the old WHO/UNICEF Product Information Sheets (PIS), the last edition of which was published in 2000. Only products included in the PQS catalogue are now recommended to be purchased by UN agencies.
Large File: 120 MB
more
If you have had COVID-19, should you still get vaccinated ? Why are we not vaccinating children under 16? WHO’s Chief Scientist Dr Soumya Swaminathan explains these and other vaccine related questions in Science in 5 this week.
The WHO Global Learning Laboratory (GLL) for Quality UHC links the experiences, expertise, and wisdom of people across the world on important issues relating to quality in the context of UHC. The GL...L is a safe space to share knowledge, experiences and ideas; to challenge ideas and approaches; and to spark new thinking for quality UHC
more
How far apart should the doses of vaccines be? What if I miss my second dose? Can I get two doses from two different manufacturers? How was safety of vaccines ensured? WHO’s Chief Scientist, Dr Soumya Swaminathan explains in Science in 5.